Efficacy of Combination Blinatumomab and Ponatinib in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph plus ALL) and Chronic Myeloid Leukemia in Lymphoid Blast Phase (CMLBP) in a Real World Setting

被引：0
|
作者：
Tobon, Katherine [1 ]
Consalvo, Kylie [2 ]
Kareem, Syeda Saba [1 ]
Lancet, Jeffrey E. [1 ]
Komrokji, Rami S. [1 ]
Pinilla-Ibarz, Javier [3 ]
Sallman, David [1 ]
Eatrides, Jennifer [4 ]
Walker, Alison R. [1 ]
Chavez, Julio C. [1 ]
Isenalumhe, Leidy Lismeris [1 ]
Shah, Bijal [1 ]
机构：
[1] H Lee Moffitt Canc Ctr & Res Inst, Dept Malignant Hematol, Tampa, FL USA
[2] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA
[3] H Lee Moffitt Canc Ctr & Res Inst, Dept Malignant Hematol, Tampa, FL USA
[4] H Lee Moffitt Canc Ctr & Res Inst, Dept Community & Satellite Oncol, Tampa, FL USA
来源：
BLOOD | 2024年 / 144卷
关键词：
D O I：
10.1182/blood-2024-201486
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：2821 / 2821
页数：1
相关论文
共 50 条
  • [31] A Phase II Study of the Combination of Decitabine, Venetoclax and Ponatinib in Patients with Chronic Myeloid Leukemia (CML) in Myeloid Blast Phase (MBP) or Philadelphia-Chromosome Positive (Ph plus ) Acute Myeloid Leukemia (AML)
    Senapati, Jayastu
    Ravandi, Farhad
    DiNardo, Courtney D.
    Issa, Ghayas C.
    Sasaki, Koji
    Konopleva, Marina
    Pemmaraju, Naveen
    Chien, Kelly S.
    Ohanian, Maro
    Jabbour, Elias
    Maiti, Abhishek
    Roy, Edith
    Delumpa, Ricardo
    Rivera, Juan
    Loiselle, Christopher
    Banks, Glenda
    Kantarjian, Hagop
    Short, Nicholas
    BLOOD, 2022, 140 : 3880 - 3882
  • [32] Olverembatinib (HQP1351) Overcomes Ponatinib Resistance in Patients with Heavily Pretreated/Refractory Chronic Myeloid Leukemia (CML) and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph plus ALL)
    Jabbour, Elias
    Koller, Paul B.
    Oehler, Vivian G.
    Jamy, Omer H.
    Mukherjee, Sudipto
    Hunter, Anthony M.
    Baer, Maria R.
    Beck, Joseph T.
    Chen, Zi
    Guo, Huanshan
    Fu, Lei
    Men, Lichuang
    Wang, Hengbang
    Yang, Dajun
    Zhai, Yifan
    Kantarjian, Hagop
    Jiang, Lixin
    Wang, Cunlin
    BLOOD, 2022, 140
  • [33] Inotuzumab ozogamicin with bosutinib for relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia or lymphoid blast phase of chronic myeloid leukemia
    Jain, Nitin
    Maiti, Abhishek
    Ravandi, Farhad
    Konopleva, Marina
    Daver, Naval
    Kadia, Tapan
    Pemmaraju, Naveen
    Short, Nicholas
    Kebriaei, Partow
    Ning, Jing
    Cortes, Jorge
    Jabbour, Elias
    Kantarjian, Hagop
    AMERICAN JOURNAL OF HEMATOLOGY, 2021, 96 (08) : 1000 - 1007
  • [34] Ponatinib, chemotherapy, and transplant in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia
    Ribera, Josep-Maria
    Garcia-Calduch, Olga
    Ribera, Jordi
    Montesinos, Pau
    Cano-Ferri, Isabel
    Martinez, Pilar
    Esteve, Jordi
    Esteban, Daniel
    Garcia-Fortes, Maria
    Alonso, Natalia
    Gonzalez-Campos, Jose
    Bermudez, Arancha
    Torrent, Anna
    Genesca, Eulalia
    Mercadal, Santiago
    Martinez-Lopez, Joaquin
    Garcia-Sanz, Ramon
    BLOOD ADVANCES, 2022, 6 (18) : 5395 - 5402
  • [35] Ponatinib vs Imatinib in Frontline Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
    Jabbour, Elias
    Kantarjian, Hagop M.
    Aldoss, Ibrahim
    Montesinos, Pau
    Leonard, Jessica T.
    Gomez-Almaguer, David
    Baer, Maria R.
    Gambacorti-Passerini, Carlo
    McCloskey, James
    Minami, Yosuke
    Papayannidis, Cristina
    Rocha, Vanderson
    Rousselot, Philippe
    Vachhani, Pankit
    Wang, Eunice S.
    Wang, Bingxia
    Hennessy, Meliessa
    Vorog, Alexander
    Patel, Niti
    Yeh, Tammie
    Ribera, Jose-Maria
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2024, 331 (21): : 1814 - 1823
  • [36] Dasatinib population pharmacokinetics in patients with chronic myeloid leukemia (CML) and Philadelphia chromosome positive acute lymphoblastic leukemia (ph plus all)
    Dai, Guowei
    Roy, Amit
    Mandava, Mohan
    Blackwood-Chirchir, Anne
    Luo, Roger
    Wu, Chiyuan
    Pfister, Marc
    JOURNAL OF CLINICAL PHARMACOLOGY, 2006, 46 (09): : 1085 - 1085
  • [37] Hyper-CVAD Plus Ponatinib as Frontline Therapy in Philadelphia Chromosome-Positive (Ph plus ) Acute Lymphoblastic Leukemia (ALL): Updated Results of a Phase II Trial
    Maiti, Abhishek
    Kantarjian, Hagop
    Ravandi, Farhad
    Short, Nicholas
    Daver, Naval
    Pemmaraju, Naveen
    Thomas, Deborah
    Yilmaz, Musa
    Kadia, Tapan
    Sasaki, Koji
    Garris, Rebecca
    Garcia-Manero, Guillermo
    DiNardo, Courtney
    Konopleva, Marina
    Estrov, Zeev
    Jain, Nitin
    Weirda, William
    Jeanis, Vicky
    Cortes, Jorge
    O'Brien, Susan
    Jabbour, Elias
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2017, 17 : S257 - S258
  • [38] Ponatinib for Chronic Myeloid Leukemia (CML) and Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph plus ALL) With History of Stem Cell Transplantation (SCT): Efficacy and Safety Results of the PACE Trial
    Nicolini, F. E.
    DeAngelo, D. J.
    Abruzzese, E.
    Apperley, J. F.
    Holyoake, T. L.
    Larson, R. A.
    Lustgarten, S.
    Rivera, V. M.
    Clackson, T.
    Conlon, M. G.
    Haluska, F. G.
    Talpaz, M.
    Cortes, J. E.
    BONE MARROW TRANSPLANTATION, 2015, 50 : S490 - S490
  • [39] Novel Abl kinase inhibitors in chronic myeloid leukemia in blastic phase and Philadelphia chromosome-positive acute lymphoblastic leukemia
    Swords, Ronan
    Alvarado, Yesid
    Giles, Francis
    CLINICAL LYMPHOMA & MYELOMA, 2007, 7 : S113 - S119
  • [40] Pharmacokinetics of Nilotinib in Pediatric Patients with Philadelphia Chromosome-Positive Chronic Myeloid Leukemia or Acute Lymphoblastic Leukemia
    Hijiya, Nobuko
    Zwaan, C. Michel
    Rizzari, Carmelo
    Foa, Robin
    Abbink, Floor
    Lancaster, Donna
    Landman-Parker, Judith
    Millot, Frederic
    Moppett, John
    Nelken, Brigitte
    Putti, Maria Caterina
    Tian, Xianbin
    Sinclair, Karen
    Santanastasio, Helene
    Buchbinder, Aby
    Kearns, Pamela
    CLINICAL CANCER RESEARCH, 2020, 26 (04) : 812 - 820
12345